A fully human antibody neutralising biologically active human TGFβ2 for use in therapy

Phage display provides a methodology for obtaining fully human antibodies directed against human transforming growth factor-beta (TGF beta) suitable for the treatment of fibrotic disorders. The strategy employed was to isolate a human single chain Fv (scFv) fragment that neutralises human TGF beta 2 from a phage display repertoire, convert it into a human IgG4 and then determine its TGF beta binding and neutralisation properties and its physical characteristics. Several scFv fragments binding to TGF beta 2 were isolated by panning of an antibody phage display repertoire, and subsequent chain shuffling of the selected VH domains with a library of V-L domains. The three most potent neutralising antibodies were chosen for conversion to IgG4 format. The IgG4 antibodies were ranked for their ability to neutralise TGF beta 2, and the most potent, 6B1 IgG4, was chosen for further characterisation. 6B1 IgG4 has a high affinity for TGF beta 2 with a dissociation constant of 0.89 nM as determined using the BIAcore biosensor and only 9% cross-reactivity with TGF beta 3 (dissociation constant, 10 nM). There was no detectable binding to TGF beta 1. 6B1 IgG4 strongly neutralises (IC50 = 2 nM) the anti-proliferative effect of TGF beta 2 in bioassays using TF1 human erythroleukaemia cells. Similarly, there was strong inhibition of binding of TGF beta 2 to cell surface receptors in a radioreceptor assay using A549 cells. 6B1 IgG4 shows no detectable cross-reactivity with related or unrelated antigens by immunocytochemistry or ELISA. The 6B1 V-L domain has entirely germline framework regions and the V-H domain has only three non-germline framework amino acids. This, together with its fully human nature: should minimise any potential immunogenicity of 6B1 IgG4 when used in therapy of fibrotic diseases mediated by TGF beta 2. (C) 1999 Elsevier Science B.V. All rights reserved.